HOME >> BIOLOGY >> NEWS
Preterm infants with RDS -- surfactant replacement therapies improves neonatal survival

Napa, CA and Parma, Italy (May 7, 2007) -- Data presented today at the Pediatric Academic Societies Annual Meeting demonstrate that premature infants with neonatal Respiratory Distress Syndrome (RDS) have a nearly 20% better chance of survival if they are treated with Curosurf (poractant alfa) Intratracheal Suspension rather than either of two competing surfactant therapies. "Differences in Mortality Among Infants Treated with Three Different Natural Surfactants for Respiratory Distress Syndrome (RDS)," a retrospective analysis of a very large database maintained by Premier Inc., considered specific procedures and clinical outcomes for 24,883 premature infants treated for RDS at 191 U.S. hospitals from January 2003 to June 2006. The alternative surfactant therapies over which Curosurf Intratracheal Suspension showed a nearly 20% mortality advantage are Survanta (beractant) and Infasurf (calfactant). Full disclosure of the data are being held pending publication.

Jatinder J. Bhatia, MD, Professor and Chief, Section of Neonatology in the Department of Pediatrics, Medical College of Georgia, commented, "Clinicians have long needed a robust basis upon which to choose surfactant therapies for premature babies suffering form RDS. Even though natural surfactants have appeared for some time to perform better than synthetic ones, and despite the significant differences in mortality that randomized trials have suggested among the three commonly available natural surfactants, there has been no single study comparing the mortality rates of all three natural surfactants."

According to Dr. Bhatia, "The present research analyzes summary data from an extensive administrative database of actual real-world clinical outcomes. The sheer size of the sample as well as the consistency of its results across different hospital settings underscores the validity of the findings. The study controlled for six variables that could have confounded results, and derive
'"/>

Contact: Harriet Ullman
harriet.ullman@fkhealth.com
617-761-6776
Feinstein Kean Healthcare
7-May-2007


Page: 1 2 3

Related biology news :

1. Pregnancy news -- Preterm delivery risk reduced by high-dose progesterone treatment
2. Preterm birth risk quickly and accurately detected with proteomic profiling
3. Prenatal stress keeps infants, toddlers up at night, study says
4. Nearly 28,000 US infants died in 2004
5. Early exposure to indoor fungus molecules may protect infants against future allergies
6. Different approach needed to protect brains of premature infants
7. Mutant gene causes severe kidney disease in infants
8. A cognitive strategy shared by human infants and our great-ape kin
9. Full year of treatment helps infants and children with toxoplasmosis
10. Key nutrients critical for older infants development
11. New observational study suggests use of combination vaccines may improve immunization coverage rates in infants

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/16/2019)... , ... June 14, 2019 , ... ... Oracle Cloud customer, will deliver a joint presentation with Versiti’s CIO at the ... 16-19 at the Rosen Shingle Creek Resort. , Versiti Vice President and Chief ...
(Date:6/11/2019)... Ind. (PRWEB) , ... June 10, 2019 , ... Improved ... in the July 2019 issue of AAPS PharmSciTech. The article was published online on ... of Improved Pharma, along with Xiaoming Sean Chen of Purdue University. , The ...
(Date:6/4/2019)... Calif. (PRWEB) , ... June 04, 2019 , ... ... technologies, today announced the appointment of Susan Murphy as the new President of ... Life Sciences?owned by Molecular Devices’ parent company, Danaher Corporation. , Since joining Molecular ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... (PRWEB) , ... June 11, 2019 , ... ... engagement, and Carilion Clinic, a national leader in opioid treatment, announced today they ... care. , Mytonomy recently deployed its virtual care platform at the ...
(Date:6/11/2019)... ... June 11, 2019 , ... ... from human mesenchymal stem cells (MSC-EV) are able to incorporate into human CD34+ ... a test on mice, MSC-EVs also increased the cells’ ability to lodge into ...
(Date:5/31/2019)... ... ... For many years, the primary forms of cancer treatment have been chemotherapy, radiation ... have led to the advent of Chimeric Antigen Receptor T (CAR T) cell therapy, ... “CARs”. The CAR enables the final product to produce chemicals in the hopes that ...
(Date:5/31/2019)... ... 2019 , ... World Compliance Seminars today announced a live ... Boston, MA. This peer recommended interactive workshop is always selected by professionals at ... off with a compendial treatment of Data Integrity fundamentals. After laying the groundwork, ...
Breaking Biology Technology:
Cached News: